An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer.

Dineen MK, Tierney DS, Kuzma P, Pentikis HS

Journal of clinical pharmacology1 Nov 2005Cited by 13 (Europe PMC)

PMID16239357DOI10.1177/0091270005281043PepBankPUB-16239357

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In men with advanced prostate cancer, histrelin hydrogel implant achieved chemical castration, reported as testosterone less than 50 ng/mL, by week 4.
In plain wordsIn men with advanced prostate cancer, histrelin hydrogel implant achieved chemical castration by week 4.
Peptide
Histrelin
Outcome
DecreaseChemical castration
Study
n = 17
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
50 microg/d · subdermal implantAs given in this study (human).
Measurements
Time to castrate testosterone
≤ 4 weeks
testosterone less than 50 ng/mL as written
Source sentences
Summary
Patients achieved chemical castration (testosterone less than 50 ng/mL) by week 4.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients with advanced prostate cancer were studied to evaluate the pharmacokinetics and pharmacodynamics of a hydrogel implant designed to deliver histrelin at a constant rate (50 microg/d) for 1 year.
Report a problemFND-1623935703
02HumanNon-randomized trialEfficacy outcome
In men receiving a replacement histrelin hydrogel implant after 52 weeks, testosterone suppression continued without interruption.
In plain wordsIn men receiving a replacement histrelin hydrogel implant, testosterone suppression continued without interruption.
Peptide
Histrelin
Outcome
Not applicableTestosterone suppression after replacement
Study
n: not reported in source
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
50 microg/d · subdermal implantAs given in this study (human).
Source sentences
Summary
In patients who had the first implant removed and received a new implant at the end of the first 52 weeks, testosterone suppression was not interrupted.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients with advanced prostate cancer were studied to evaluate the pharmacokinetics and pharmacodynamics of a hydrogel implant designed to deliver histrelin at a constant rate (50 microg/d) for 1 year.
Report a problemFND-1623935704
03HumanNon-randomized trialPharmacokinetics
In men with advanced prostate cancer, mean serum histrelin levels were approximately 0.265 ng/mL over 52 weeks of histrelin hydrogel implant treatment.
In plain wordsIn men with advanced prostate cancer, blood histrelin levels averaged about 0.265 ng/mL over 52 weeks with the implant.
Peptide
Histrelin
Outcome
Not applicableMean serum histrelin over 52 weeks
Study
n = 17
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50 microg/d · subdermal implant · 52 weeksAs given in this study (human).
Measurements
Mean serum histrelin over 52 weeks
≈ 0.265 ng/mL
17 men with advanced prostate cancer
Source sentences
Summary
The histrelin subdermal implant delivered constant histrelin levels, with mean serum histrelin of approximately 0.265 ng/mL over 52 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients with advanced prostate cancer were studied to evaluate the pharmacokinetics and pharmacodynamics of a hydrogel implant designed to deliver histrelin at a constant rate (50 microg/d) for 1 year.
Report a problemFND-1623935701
04HumanNon-randomized trialPharmacokinetics
In men with advanced prostate cancer, mean serum histrelin concentration at 52 weeks of a hydrogel implant delivering 50 microg/d was 0.128 +/- 0.0652 ng/mL.
In plain wordsIn men with advanced prostate cancer, average blood histrelin level at 52 weeks of the implant was 0.128 ng/mL.
Peptide
Histrelin
Outcome
Not applicableSerum histrelin at 52 weeks
Study
n = 17
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50 microg/d · subdermal implant · 52 weeksAs given in this study (human).
Measurements
Mean serum histrelin
0.128 ng/mL
end of 52 weeks
Serum histrelin dispersion (+/- as written)
0.0652 ng/mL
end of 52 weeks
Source sentences
Summary
At the end of 52 weeks, mean histrelin concentrations were 0.128 +/- 0.0652 ng/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen patients with advanced prostate cancer were studied to evaluate the pharmacokinetics and pharmacodynamics of a hydrogel implant designed to deliver histrelin at a constant rate (50 microg/d) for 1 year.
Report a problemFND-1623935702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.